TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04478240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PeerLearning.net
Description: PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group.
Study: NCT04663061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical weight loss
Description: Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes education
Description: Participants will receive standard of care diabetes education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Participants will use CGM devices to track blood glucose levels in near real time
Study: NCT04804540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion
Study: NCT05183815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: slow stroke massage and murrotal quran
Description: murrotal quran and slow stroke massage
Study: NCT06530225

Intervention type: OTHER
Intervention: Education and Mentoring for Prescribing Pharmacists
Description: Pharmacists enrolled in the PrEP prescribing cohort will receive implicit bias, health disparity and health equity training for HIV prevention. In addition, the pharmacists will receive mentorship and receive an implementation toolkit on best practices for PrEP prescribing.
Study: NCT05578248

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Non-invasive imaging technology that produces three-dimensional detailed anatomical images

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Non-invasive imaging technology that produces three-dimensional detailed anatomical images

Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee

Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
Study: NCT06462144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-514 CART Cell Injection
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study: NCT04499131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
Study: NCT05578079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Intervention-1 group will listen to the classical music that the Arts of Fugue by Bach.
Study: NCT05578079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Intervention-2 group will listen to lullaby.
Study: NCT06331026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation
Study: NCT04499131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Cycle (no intervention)
Description: Control group of 19 subjects in the context of a natural cycle with only endogenous progesterone present
Study: NCT05515796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terelizumab (aka Tislelizumab)
Description: q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terelizumab (aka Tislelizumab)
Description: q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
Study: NCT06331026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation
Study: NCT05515796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terelizumab (aka Tislelizumab)
Description: q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOx
Description: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
Study: NCT05149872

Intervention type: OTHER
Group type: OTHER
Intervention: Reversal
Description: Sugamamdex will be used to reverse muscle relaxation
Study: NCT06284304

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalated radiotherapy
Description: 5 fraction de-escalated dose SBRT protocol
Study: NCT05515796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOx
Description: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOx
Description: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 25 Gy/5 fractions
Study: NCT06331026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (R)
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT04784065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand orthosis
Description: An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand orthosis
Description: An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
Study: NCT06176144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
Study: NCT06331026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (R)
Description: A single subcutaneous injection of PEG-rhGH with present preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (R)
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT05355051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Given by Vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by Vein (IV)
Study: NCT05414877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: vasopressor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: vasopressor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: vasopressor
Study: NCT05811832

Intervention type: OTHER
Intervention: Evaluation
Description: Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
Study: NCT05648500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Study: NCT06275971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Glycemic control was monitored using CGM data for seven days following cardiac surgery
Study: NCT05484609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OUD scenario
Description: The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes scenario
Description: The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
Study: NCT03934996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Runners with educational training
Description: Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics
Study: NCT05735418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GI Biome #7
Description: It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10\^8 CFU/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
Study: NCT06548477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.
Study: NCT04901546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient's own saliva
Description: Infants with esophageal atresia will be given their own saliva
Study: NCT06644079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Participants will self-apply topical tranexamic acid to the area where their disease is located 3 times daily for 21-28 days prior to their scheduled Moh's or excision surgery.
Study: NCT06644794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone-modified natural cycle preparation for frozen embryo transfer
Description: A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone replacement therapy cycle preparation for frozen embryo transfer
Description: A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
Study: NCT05748080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eating apples
Description: the eating of 2 apples a day for a period of 6 weeks
Study: NCT06639243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QYM Technique
Description: The intervention in this study involves the application of the Quick Yielding Modified (QYM) technique for the treatment of complex aortic arch diseases. This procedure consists of two main components:~1. Thoracic Endovascular Aortic Repair (TEVAR): This minimally invasive procedure utilizes a covered stent graft to exclude the diseased segment of the thoracic aorta, providing immediate protection against rupture and controlling blood flow.~2. In Situ Fenestration and Revascularization of Supra-Aortic Branches: Following TEVAR, the QYM technique includes creating fenestrations in the stent graft to allow for the revascularization of the supra-aortic branches (such as the brachiocephalic, left common carotid, and left subclavian arteries). This is achieved through direct puncture and reconstruction of the branch vessels, ensuring adequate blood flow to these critical arteries while preserving their function.~The combination of these techniques aims to achieve effective treatment out
Study: NCT06641895

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BBM-D101
Description: BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment. It is a suspension for single intravenous (IV) infusion.
Study: NCT06642467

Intervention type: DEVICE
Intervention: BGEM
Description: BGEM is an ai driven model to predict blood glucose using ppg sensor

Intervention type: DEVICE
Intervention: BGEM
Description: BGEM is an ai driven model to predict blood glucose using ppg sensor
Study: NCT06641544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inetetamab
Description: Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
Study: NCT06640777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEAF-4L6715
Description: LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
Study: NCT06636695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix
Description: Group 1 (Cellular Matrix): Patients randomized to this group will be treated with two intra-articular injections of Cellular Matrix at D0 and M1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthovisc
Description: Group 2 (HA): Patients randomized to this group will be treated with two intra-articular injections of HA alone provided by ORTHOVISC at D0 and M1
Study: NCT06639022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block
Description: Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group without peripheral nerve block
Description: In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study: NCT06638216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment
Description: Frailty is assessed using the G8 questionnaire.~Secondary objectives include the assessment of quality of life and financial burden (EORTC-QLQ C30+ H\&N43), swallowing function, cardiopulmonary resilience (6-minute walk test) and the patient's wishes regarding a prehabilitation program. Epidemiological and disease-related data is also collected.
Study: NCT06640218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sealer activation with Eddy sonic and AF max
Description: activation of sealer after cleaning and shaping, before the obturation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sealer activation with Eddy sonic and AF max
Description: activation of sealer after cleaning and shaping, before the obturation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without AF max or Eddy sonic sealer activation
Description: sealer without activation
Study: NCT06640309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide Tablet
Description: Nicotinamide is anti-inflammatory and antioxidant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional synthetic antirheumatic drugs
Description: methotrexate- leflunomide- sulfasalazine- hydroxychloroquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional synthetic antirheumatic drugs
Description: methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
Study: NCT06638515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking apnea at Low Lung Volume
Description: Walking apnea at low Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking at normal breathing
Description: Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
Study: NCT06642883

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prolife
Description: randomized in a 1:1 ratio to treatment :1 vial/day for 60 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 vial/day for 60 days.
Study: NCT06642987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Test 20mg
Description: 1 tablets orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan Reference 20mg
Description: 1 tablets orally once a day
Study: NCT06644508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strict adherence to European guidelines
Description: The goal is to maintain a neutral fluid balance throughout the course of intubation if clinical practice allows. Therefore:~* From the start of mechanical ventilation, the maximum maintenance fluids is 65% of the maintenance fluids proposed by the Holliday \& Segar formula. Fluid resuscitation in the first hours after intubation is at the discretion of the attending physician.~* Any other interventions to maintain a neutral fluid balance (e.g., starting diuretics, reducing fluid boluses, decreasing creep fluids, or using more concentrated enteral feeding) are at the discretion of the attending physician.~* Throughout the intervention, the attending physician decides if clinical practice allows for a decrease in fluid balance, and international feeding goals must always be met.
Study: NCT05435963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Description: A typical PR program will include exercise training, disease-specific and self-management strategies education, and will last 6 - 8 weeks
Study: NCT06643780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: 60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolendronic Acid
Description: 5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months